Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Placebo; Drug: BI 1356 BS, low dose; Drug: BI 1356 BS, high dose; Drug: BI 1356 BS, medium dose

Study type: Interventional

Funder types: Industry

Identifiers

NCT02183415

1218.3

Details and patient eligibility

About

Study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS during 4 week treatment duration

Enrollment: 77 patients

Sex: All

Ages: 21 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female postmenopausal patients with proven diagnose of type 2 diabetes mellitus treated with diet and exercise only or with one (or two) oral hypoglycaemic agents besides glitazones

• Glycosylated haemoglobin A1 (HbA1c)

  • ≤ 8.5 % at screening for patients treated with diet and exercise and/or one oral hypoglycaemic agent or
  • ≤ 8.0 % at screening for patients treated with two oral hypoglycaemic agents

• Male patients: Age ≥21 and Age ≤70 years

• Female patients: Age ≥60 and Age ≤70 years

• BMI ≥18.5 and BMI ≤35 kg/m2 (Body Mass Index)

• Caucasian ethnicity

• Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion criteria

• Any finding of the medical examination (including Blood Pressure, Pulse Rate and Electrocardiogram) deviating from normal and of not acceptable clinical relevance
• Clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency NYHA (New York Heart Association) II-IV, known cardiovascular diseases including hypertension > 150/95mmHg, stroke and TIA (transient ischemic attack)
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and medically treated hypertension
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or relevant neurological disorders besides polyneuropathy
• Chronic or relevant acute infections (e.g. HIV, Hepatitis)
• History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
• Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial except allowed co-medication
• Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
• Participation in another trial with an investigational drug within two months prior to administration or during the trial
• Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
• Inability to refrain from smoking on trial days
• Alcohol abuse (more than 40 g/day = 5 units/day)
• Drug abuse
• Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
• Excessive physical activities (within one week prior to administration or during the trial)
• Any laboratory value outside the reference range and the clinical relevance is not acceptable (or the value is more than three times higher than the upper limit of the normal range e.g. liver enzymes)
• Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic salicylic acid and statins) within the last 3 months
• Fasted blood glucose > 240 mg/dl (=13.3 mmol/L) on two consecutive days during washout
• Serum creatinine above upper limit of normal at screening

Male Patients:

• Not willing to use adequate contraception (condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake

Female patients:

• Positive pregnancy test

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

77 participants in 4 patient groups, including a placebo group

BI 1356 BS, low dose

Experimental group

Treatment:

Drug: BI 1356 BS, low dose

BI 1356 BS, medium dose

Experimental group

Treatment:

Drug: BI 1356 BS, medium dose

BI 1356 BS, high dose

Experimental group

Treatment:

Drug: BI 1356 BS, high dose

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo